AUPH Aurinia Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why AUPH matters now
Aurinia Pharmaceuticals Inc. (AUPH) is a US stock in Healthcare. The latest InvestLog snapshot shows $15.78 with -4.88% on the session and $2.03B in market capitalization; recent performance reads 1-month +5.85% and YTD +3.20%.
The latest financial table shown here is Q1 2026, with revenue of $77.7M, net income of $34.4M, and EPS of $0.25. Investors can compare that operating picture with valuation signals such as P/E 7.30 and FCF yield 7.8%.
The latest indexable market news headline is "Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis" from GuruFocus.
Additional event context on this page matters because analyst consensus is Hold with a median target of $13.00; recent insider activity includes Bailey Jeffrey Allen filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
7.30
PEG
0.00
P/B
3.84
P/S
7.10
EV/EBITDA
13.25
DCF Value
$-49.08
FCF Yield
7.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.7%
Operating Margin
41.7%
Net Margin
100.0%
ROE
64.5%
ROA
41.2%
ROIC
19.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $77.7M | $34.4M | $0.25 |
| Q4 2025 | $77.1M | $210.8M | $1.53 |
| FY 2025 | $283.1M | $287.2M | $2.07 |
| Q3 2025 | $73.5M | $31.6M | $0.23 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$12.60
Target (Median)
$13.00
Target Range
$6.00 - $16.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.43
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.